View in EDS

Preclinical response of uveal melanomas to the velcrin compound, BAY 2666605.

Saved in:
Bibliographic Details
Title: Preclinical response of uveal melanomas to the velcrin compound, BAY 2666605.
Authors: Kotýnková K; Broad Institute Cambridge, MA United States., Andersen S; Broad Institute Cambridge, MA United States., Denney D; Broad Institute Cambridge, MA United States., Karsli Uzunbas G; Broad Institute Cambridge, MA United States., Burri M; Broad Institute Cambridge, MA United States., Wu X; Broad Institute Cambridge, MA United States., Kaplan B; Broad Institute Cambridge, MA United States., Haq R; Dana-Farber Cancer Institute Boston, MA United States., Meyerson M; Dana-Farber Cancer Institute Boston, MA United States., Greulich H; Broad Institute Cambridge, MA United States.
Source: Molecular cancer therapeutics [Mol Cancer Ther] 2026 Jun 02. Date of Electronic Publication: 2026 Jun 02.
Publication Type: Journal Article
Journal Info: Publisher: American Association for Cancer Research, Inc Country of Publication: United States NLM ID: 101132535 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1538-8514 (Electronic) Linking ISSN: 15357163 NLM ISO Abbreviation: Mol Cancer Ther Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42227579
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Preclinical response of uveal melanomas to the velcrin compound, BAY 2666605.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Kotýnková+K%22">Kotýnková K</searchLink>; Broad Institute Cambridge, MA United States.<br /><searchLink fieldCode="AU" term="%22Andersen+S%22">Andersen S</searchLink>; Broad Institute Cambridge, MA United States.<br /><searchLink fieldCode="AU" term="%22Denney+D%22">Denney D</searchLink>; Broad Institute Cambridge, MA United States.<br /><searchLink fieldCode="AU" term="%22Karsli+Uzunbas+G%22">Karsli Uzunbas G</searchLink>; Broad Institute Cambridge, MA United States.<br /><searchLink fieldCode="AU" term="%22Burri+M%22">Burri M</searchLink>; Broad Institute Cambridge, MA United States.<br /><searchLink fieldCode="AU" term="%22Wu+X%22">Wu X</searchLink>; Broad Institute Cambridge, MA United States.<br /><searchLink fieldCode="AU" term="%22Kaplan+B%22">Kaplan B</searchLink>; Broad Institute Cambridge, MA United States.<br /><searchLink fieldCode="AU" term="%22Haq+R%22">Haq R</searchLink>; Dana-Farber Cancer Institute Boston, MA United States.<br /><searchLink fieldCode="AU" term="%22Meyerson+M%22">Meyerson M</searchLink>; Dana-Farber Cancer Institute Boston, MA United States.<br /><searchLink fieldCode="AU" term="%22Greulich+H%22">Greulich H</searchLink>; Broad Institute Cambridge, MA United States.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101132535%22">Molecular cancer therapeutics</searchLink> [Mol Cancer Ther] 2026 Jun 02. <i>Date of Electronic Publication: </i>2026 Jun 02.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Association+for+Cancer+Research%2C+Inc%22">American Association for Cancer Research, Inc </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101132535 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1538-8514 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2215357163%22">15357163 </searchLink><i>NLM ISO Abbreviation: </i>Mol Cancer Ther <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42227579
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1158/1535-7163.MCT-25-1473
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: Preclinical response of uveal melanomas to the velcrin compound, BAY 2666605.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Kotýnková K
      – PersonEntity:
          Name:
            NameFull: Andersen S
      – PersonEntity:
          Name:
            NameFull: Denney D
      – PersonEntity:
          Name:
            NameFull: Karsli Uzunbas G
      – PersonEntity:
          Name:
            NameFull: Burri M
      – PersonEntity:
          Name:
            NameFull: Wu X
      – PersonEntity:
          Name:
            NameFull: Kaplan B
      – PersonEntity:
          Name:
            NameFull: Haq R
      – PersonEntity:
          Name:
            NameFull: Meyerson M
      – PersonEntity:
          Name:
            NameFull: Greulich H
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 02
              M: 06
              Text: 2026 Jun 02
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1538-8514
          Titles:
            – TitleFull: Molecular cancer therapeutics
              Type: main
ResultId 1